Publicacións (31) Publicacións de Francisco Javier Afonso Afonso

2022

  1. FRAGILE-COLCOVID19: A Clinical Trial Based on Early Administration of an Oral Combination of Colchicine and Prednisone in Elderly Patients with COVID-19 in Geriatric Facilities

    Clinical Drug Investigation, Vol. 42, Núm. 11, pp. 949-964

2021

  1. Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group

    Journal of Geriatric Oncology, Vol. 12, Núm. 3, pp. 410-415

2020

  1. PD-(L)1 inhibitors in combination with chemotherapy as first-line treatment for non-small-cell lung cancer: A pairwise meta-analysis

    Journal of Clinical Medicine, Vol. 9, Núm. 7, pp. 1-13

2019

  1. Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer

    Clinical and Translational Oncology, Vol. 21, Núm. 3, pp. 249-258

  2. EP1.14-15 Real World Clinical Experience of the Galician Lung Cancer Group: Afatinib in Patients with EGFR Positive Mutation

    Journal of Thoracic Oncology, Vol. 14, Núm. 10, pp. S1037

  3. Efficacy and safety of Crizotinib in patients with ALK positive non small cell lung cancer (NSCLC): Real-world findings.

    Journal of Clinical Oncology, Vol. 37, Núm. 15_suppl, pp. e20636-e20636

  4. Evaluation of the lung immune prognostic index in advanced nonsmall cell lung cancer patients under nivolumab monotherapy

    Translational Lung Cancer Research, Vol. 8, Núm. 6, pp. 1078-1085

  5. Galician lung cancer group: Afatinib's data as first-line treatment for elderly patients

    JOURNAL OF CLINICAL ONCOLOGY, Vol. 37, Núm. 15 Sup, pp. e20662

  6. Immune checkpoint inhibitors (ICI) in combination with chemotherapy as first-line (1L) treatment for non-small cell lung cancer (NSCLC): A pair-wise meta-analysis (MA)

    Annals of Oncology, Vol. 30, pp. xi43

  7. Third and successive–lines of chemotherapy in NSCLC patients without therapeutic targets: Experience of the Grupo Gallego de Cáncer de Pulmón.

    Journal of Clinical Oncology, Vol. 37, Núm. 15_suppl, pp. e20579-e20579

2018

  1. Concurrent chemoradiation for locally advanced stage III non-small cell lung cancer with cisplatin, vinorelbine, and thoracic radiotherapy: a phase II study from the Galician Lung Cancer Group

    Clinical and Translational Oncology, Vol. 20, Núm. 11, pp. 1467-1473

  2. Real world data of nivolumab for previously treated non-small cell lung cancer patients: A Galician lung cancer group clinical experience

    Translational Lung Cancer Research, Vol. 7, Núm. 3, pp. 404-415

2016

  1. EGFR testing and clinical management of advanced NSCLC: A galician lung cancer group study (GGCP 048-10)

    Cancer Management and Research, Vol. 8, pp. 11-20

  2. Fluorescence in situ hybridization analysis of the ALK gene in 2,045 non-small cell lung cancer patients from North-Western Spain (Galicia)

    Oncology Letters, Vol. 12, Núm. 2, pp. 1403-1407

  3. Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

    BMC Cancer, Vol. 16, Núm. 1

  4. Prostate cancer perspectives after chaarted: Optimizing treatment sequence

    Critical Reviews in Oncology/Hematology, Vol. 107, pp. 119-127

2015

  1. Carboplatin-Pemetrexed Combination in Elderly Patients with Advanced Non-Squamous Non Small Cell Lung Cancer (NS-NSCLC)

    JOURNAL OF THORACIC ONCOLOGY, Vol. 10, Núm. 9 Sup2, pp. S657-S657

  2. Enzalutamide: A new prostate cancer targeted therapy against the androgen receptor

    Cancer Treatment Reviews, Vol. 41, Núm. 3, pp. 247-253

  3. Paclitaxel and Irinotecan in Platinum Refractory/Resistant Small Cell Lung Cancer: Final Analisis of One Galician Lung Cancer Group Experience

    JOURNAL OF THORACIC ONCOLOGY, Vol. 10, Núm. 9 Sup2, pp. S497-S498

  4. Radium-223 dichloride: A new paradigm in the treatment of prostate cancer

    Expert Review of Anticancer Therapy, Vol. 15, Núm. 3, pp. 339-348